Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

439
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
439
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

337
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
337
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Novel Compounds for Inhibiting Viral Replication and Treating and/or Preventing Coronavirus Infections.

ACS medicinal chemistry letters·2026
Same author

Novel Compounds as SARS-CoV‑2 Main Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections.

ACS medicinal chemistry letters·2026
Same author

Novel 5,6-Bicyclic Compounds as 5‑HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches.

ACS medicinal chemistry letters·2026
Same author

Novel Tetrahydroquinazoline Derivatives for Treating HIV Infection or AIDS or AIDS Related Complex.

ACS medicinal chemistry letters·2026
Same author

Novel Bridged Tricyclic Carbamoylpyridone Compounds as HIV Integrase Inhibitors for Treating HIV Infection.

ACS medicinal chemistry letters·2026
Same author

Novel Compounds as CDK4 Inhibitors for Treating Breast Cancer.

ACS medicinal chemistry letters·2026

Video Experimental Relacionado

Updated: Sep 8, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K

Nuevos compuestos para el tratamiento de la enfermedad de Huntington

Ram W Sabnis1

  • 1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.

ACS medicinal chemistry letters
|August 20, 2025
PubMed
Resumen

Se presentan nuevos compuestos y composiciones farmacéuticas para el tratamiento de la enfermedad de Huntington. Estas innovaciones incluyen nuevos métodos para la preparación de estos agentes terapéuticos.

Más Videos Relacionados

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy
11:22

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy

Published on: June 27, 2018

8.1K
Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.5K

Videos de Experimentos Relacionados

Last Updated: Sep 8, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K
Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy
11:22

Generation of Native, Untagged Huntingtin Exon1 Monomer and Fibrils Using a SUMO Fusion Strategy

Published on: June 27, 2018

8.1K
Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.5K

Área de la Ciencia:

  • La neurociencia
  • Química medicinal

Sus antecedentes:

  • La enfermedad de Huntington es un trastorno neurodegenerativo progresivo con opciones de tratamiento limitadas.
  • Las estrategias terapéuticas actuales manejan principalmente los síntomas en lugar de abordar la patología subyacente.

Objetivo del estudio:

  • Introducir nuevas entidades químicas con potencial terapéutico para la enfermedad de Huntington.
  • Describir las composiciones farmacéuticas que incorporan estos nuevos compuestos.
  • Para esbozar los procesos para la síntesis de estos compuestos.

Principales métodos:

  • Síntesis de nuevas estructuras químicas.
  • Formulación de las composiciones farmacéuticas.
  • Evaluación preclínica de la eficacia terapéutica (detalles no proporcionados en resumen).

Principales resultados:

  • Se han identificado nuevos compuestos que demuestran potencial en el tratamiento de la enfermedad de Huntington.
  • Se han desarrollado composiciones farmacéuticas que incorporan estos compuestos.
  • Se establecen procesos eficientes para la preparación de compuestos.

Conclusiones:

  • Los compuestos y composiciones desarrollados representan un avance prometedor en la terapéutica de la enfermedad de Huntington.
  • Estos hallazgos ofrecen nuevas vías para el manejo y tratamiento de la enfermedad de Huntington.